Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: Contraindications/Warnings/Precautions/Adverse effects
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Contraindications/Warnings/Precautions/Adverse effects

3 evidence topics · 3 sources

Warnings and precautions

Safety precautions: Japan

“Oculomucocutaneous syndrome (Stevens-Johnson syndrome) or toxic epidermal necrolysis (TEN)” (opens the source at this quote in a new tab)
“Administration should be permanently discontinued.” (opens the source at this quote in a new tab)

Toxic epidermal necrolysis: DLBCL case report

“We present a case of a 74-year-old man with refractory DLBCL who developed TEN after 1 month of tirabrutinib treatment.” (opens the source at this quote in a new tab)

Skin-related adverse events across B-cell malignancies

“PCNSL and WM patients were most susceptible to skin-related AEs.” (opens the source at this quote in a new tab)